Galecto Inc (GLTO)

$6.85

-0.27

(-3.79%)▲

Live

Performance

  • $6.84
    $7.06
    $6.85
    downward going graph

    0.15%

    Downside

    Day's Volatility :3.07%

    Upside

    2.93%

    downward going graph
  • $6.50
    $23.50
    $6.85
    downward going graph

    5.11%

    Downside

    52 Weeks Volatility :72.34%

    Upside

    70.85%

    downward going graph

Returns

PeriodGalecto IncIndex (Russel 2000)
3 Months
-46.24%
0.0%
6 Months
-58.18%
0.0%
1 Year
-50.04%
0.0%
3 Years
-91.89%
-23.0%

Highlights

Market Capitalization
8.8M
Book Value
$21.74
Earnings Per Share (EPS)
-23.25
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.17%
Return On Equity TTM
-75.57%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-21.9M
Diluted Eps TTM
-23.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-23.16
EPS Estimate Next Year
-20.93
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Galecto Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 45.99%

Current $6.85
Target $10.00

Technicals Summary

Sell

Neutral

Buy

Galecto Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Galecto Inc
Galecto Inc
-40.77%
-58.18%
-50.04%
-91.89%
-98.1%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Galecto Inc
Galecto Inc
NA
NA
NA
-23.16
-0.76
-0.32
NA
21.74
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Galecto Inc
Galecto Inc
Buy
$8.8M
-98.1%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Galecto Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 132.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 136.7%

Institutional Holdings

  • Novo A/S

    9.21%

  • Renaissance Technologies Corp

    2.14%

  • Vanguard Group Inc

    0.82%

  • Geode Capital Management, LLC

    0.79%

  • Susquehanna International Group, LLP

    0.62%

  • Citadel Advisors Llc

    0.47%

Company Information

galecto biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. the company’s products target galectins, a group of proteins that play important roles in many disorders. galecto biotech’s high potency galectin modulators may open new treatment possibilities for many patients. the company, which is located in lund, sweden, is led by top-level scientists and biotech executives.

Organization
Galecto Inc
Employees
13
CEO
Dr. Hans T. Schambye M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs